Chr t(15;17)	Acute Promyelocytic Leukemia	Chr t(15;17)	Acute Promyelocytic Leukemia	arsenic trioxide Sensitive: A1 - Approval arsenic trioxide Sensitive : A1	arsenic trioxide Sensitive: A1 - Approval arsenic trioxide Sensitive : A1
PML-RARA fusion	Acute Promyelocytic Leukemia	PML-RARA fusion	Acute Promyelocytic Leukemia	arsenic trioxide Sensitive: A1 - Approval arsenic trioxide Sensitive : A1	arsenic trioxide Sensitive: A1 - Approval arsenic trioxide Sensitive : A1
No biomarker	Acute Promyelocytic Leukemia	No biomarker	Acute Promyelocytic Leukemia	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2
No biomarker	Acute Promyelocytic Leukemia	No biomarker	Acute Promyelocytic Leukemia	cytarabine + daunorubicin Sensitive: A2 - Guideline cytarabine + daunorubicin Sensitive : A2	cytarabine + daunorubicin Sensitive: A2 - Guideline cytarabine + daunorubicin Sensitive : A2
PML-RARA fusion	Acute Promyelocytic Leukemia	PML-RARA fusion	Acute Promyelocytic Leukemia	tretinoin + arsenic trioxide Sensitive: C3 – Early Trials tretinoin + arsenic trioxide Sensitive : C3	tretinoin + arsenic trioxide Sensitive: C3 – Early Trials tretinoin + arsenic trioxide Sensitive : C3
STAT5b-RARA fusion	Acute Promyelocytic Leukemia	STAT5b-RARA fusion	Acute Promyelocytic Leukemia	DCAG Sensitive: C4 – Case Studies DCAG Sensitive : C4	DCAG Sensitive: C4 – Case Studies DCAG Sensitive : C4
PML-RARA fusion	Acute Promyelocytic Leukemia	PML-RARA fusion	Acute Promyelocytic Leukemia	cytarabine + idarubicin hydrochloride + tretinoin Sensitive: C4 – Case Studies cytarabine + idarubicin hydrochloride + tretinoin Sensitive : C4	cytarabine + idarubicin hydrochloride + tretinoin Sensitive: C4 – Case Studies cytarabine + idarubicin hydrochloride + tretinoin Sensitive : C4
FLT3-ITD mutation + PML-RARA fusion + WT1 overexpression	Acute Promyelocytic Leukemia	FLT3-ITD mutation + PML-RARA fusion + WT1 overexpression	Acute Promyelocytic Leukemia	cytarabine + idarubicin hydrochloride + arsenic trioxide + hydroxyurea Sensitive: C4 – Case Studies cytarabine + idarubicin hydrochloride + arsenic trioxide + hydroxyurea Sensitive : C4	cytarabine + idarubicin hydrochloride + arsenic trioxide + hydroxyurea Sensitive: C4 – Case Studies cytarabine + idarubicin hydrochloride + arsenic trioxide + hydroxyurea Sensitive : C4
PML-RARA T285I	Acute Promyelocytic Leukemia	PML-RARA T285I	Acute Promyelocytic Leukemia	venetoclax Sensitive: C4 – Case Studies venetoclax Sensitive : C4	venetoclax Sensitive: C4 – Case Studies venetoclax Sensitive : C4
ZBTB16-RARA fusion	Acute Promyelocytic Leukemia	ZBTB16-RARA fusion	Acute Promyelocytic Leukemia	chidamide Sensitive: D – Preclinical chidamide Sensitive : D	chidamide Sensitive: D – Preclinical chidamide Sensitive : D
STAT5b-RARA fusion	Acute Promyelocytic Leukemia	STAT5b-RARA fusion	Acute Promyelocytic Leukemia	chidamide Sensitive: D – Preclinical chidamide Sensitive : D	chidamide Sensitive: D – Preclinical chidamide Sensitive : D
NPM-RARA fusion	Acute Promyelocytic Leukemia	NPM-RARA fusion	Acute Promyelocytic Leukemia	chidamide Sensitive: D – Preclinical chidamide Sensitive : D	chidamide Sensitive: D – Preclinical chidamide Sensitive : D

Acute Promyelocytic Leukemia

Associations(12)

Associations
(12)